Amrutanjan Health Care Limited, established in 1936, is a prominent Indian pharmaceutical company with its headquarters situated in Chennai, Tamil Nadu. The company has a rich history, dating back to its foundation by Kasinadhuni Nageswara Rao in Bombay (now Mumbai) in 1893.
With a current market capitalization of ₹2,169 crore and a share price of ₹750 (as of 16th June 2024), Amrutanjan Healthcare has solidified its position in the healthcare industry. The company’s longstanding presence and commitment to quality have earned it a reputable stature in the Indian market, making it a trusted name in pharmaceuticals.
Amrutanjan Health Care Ltd Excels with Strong Revenue Growth but Faces Quarterly Profit Margin Challenges
- Amrutanjan Health Care Ltd reported ₹132.01Cr in revenue for Q4 FY2023-2024, up by 25.56% from the previous year and 9.32% from the previous quarter.
- Net profits for the quarter were ₹13.66Cr, showing a 7.56% increase year-over-year but a significant 21.72% decrease from the previous quarter.
- The net profit margin decreased to 10.35% in Q4 FY2023-2024, down by 14.33% compared to the same period last year and 28.39% from the previous quarter.
Below are the trading platforms that you can use to purchase Amrutanjan Health Care shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| June 2024 | 810.00 | 704.35 |
| July 2024 | 801.90 | 697.30 |
| August 2024 | 833.98 | 725.20 |
| September 2024 | 867.34 | 754.20 |
| October 2024 | 850.33 | 739.42 |
| November 2024 | 875.84 | 761.60 |
| December 2024 | 897.73 | 780.64 |
In 2024, Amrutanjan Health Care Ltd (AHCL) shows a promising trajectory for its share price, with projections indicating a steady increase throughout the year. Starting at a minimum of 704.35 in June, the share price is expected to reach a maximum of 897.73 by December. This upward trend suggests robust investor confidence and positive market sentiment surrounding AHCL.
July marks a slight dip to 697.30, but subsequent months see consistent gains, peaking in December with an anticipated maximum price of 897.73. These projections reflect AHCL’s strong performance and strategic positioning within the healthcare sector, offering potential growth opportunities for investors throughout the year.
| When | Maximum Price | Minimum Price |
| January 2025 | 915.69 | 704.38 |
| February 2025 | 939.17 | 722.44 |
| March 2025 | 975.80 | 750.61 |
| April 2025 | 956.66 | 735.89 |
| May 2025 | 928.80 | 714.46 |
| June 2025 | 970.59 | 746.61 |
| July 2025 | 951.56 | 731.97 |
| August 2025 | 980.99 | 754.61 |
| September 2025 | 1,015.33 | 781.02 |
| October 2025 | 1,041.73 | 801.33 |
| November 2025 | 1,067.77 | 821.36 |
| December 2025 | 1,094.46 | 841.90 |
Amrutanjan Health Care Ltd’s share price targets for 2025 show a consistent upward trend, reaching from a minimum of 704.38 in January to a maximum of 1,094.46 by December.
| When | Maximum Price | Minimum Price |
| January 2026 | 1,127.30 | 867.15 |
| February 2026 | 1,156.20 | 889.39 |
| March 2026 | 1,201.29 | 924.07 |
| April 2026 | 1,177.74 | 905.95 |
| May 2026 | 1,143.44 | 879.57 |
| June 2026 | 1,194.89 | 919.15 |
| July 2026 | 1,171.46 | 901.12 |
| August 2026 | 1,207.69 | 928.99 |
| September 2026 | 1,249.96 | 961.51 |
| October 2026 | 1,282.46 | 986.51 |
| November 2026 | 1,314.52 | 1,011.17 |
| December 2026 | 1,347.39 | 1,036.45 |
| When | Maximum Price | Minimum Price |
| January 2027 | 1,374.33 | 1,057.18 |
| February 2027 | 1,409.57 | 1,084.29 |
| March 2027 | 1,464.55 | 1,126.57 |
| April 2027 | 1,435.83 | 1,104.48 |
| May 2027 | 1,394.01 | 1,072.31 |
| June 2027 | 1,456.74 | 1,120.57 |
| July 2027 | 1,428.18 | 1,098.60 |
| August 2027 | 1,472.35 | 1,132.57 |
| September 2027 | 1,523.88 | 1,172.21 |
| October 2027 | 1,563.50 | 1,202.69 |
| November 2027 | 1,602.59 | 1,232.76 |
| December 2027 | 1,642.65 | 1,263.58 |
| When | Maximum Price | Minimum Price |
| January 2028 | 1,675.50 | 1,288.85 |
| February 2028 | 1,718.47 | 1,321.90 |
| March 2028 | 1,785.49 | 1,373.45 |
| April 2028 | 1,750.48 | 1,346.52 |
| May 2028 | 1,699.49 | 1,307.30 |
| June 2028 | 1,775.97 | 1,366.13 |
| July 2028 | 1,741.15 | 1,339.34 |
| August 2028 | 1,795.00 | 1,380.77 |
| September 2028 | 1,857.82 | 1,429.09 |
| October 2028 | 1,906.12 | 1,466.25 |
| November 2028 | 1,953.78 | 1,502.91 |
| December 2028 | 2,002.62 | 1,540.48 |
| When | Maximum Price | Minimum Price |
| January 2029 | 2,042.67 | 1,571.29 |
| February 2029 | 2,095.05 | 1,611.58 |
| March 2029 | 2,176.76 | 1,674.43 |
| April 2029 | 2,134.08 | 1,641.60 |
| May 2029 | 2,071.92 | 1,593.78 |
| June 2029 | 2,165.16 | 1,665.50 |
| July 2029 | 2,122.70 | 1,632.85 |
| August 2029 | 2,188.35 | 1,683.35 |
| September 2029 | 2,264.94 | 1,742.26 |
| October 2029 | 2,323.83 | 1,787.56 |
| November 2029 | 2,381.93 | 1,832.25 |
| December 2029 | 2,441.48 | 1,878.06 |
| When | Maximum Price | Minimum Price |
| January 2030 | 2,490.31 | 1,915.62 |
| February 2030 | 2,554.16 | 1,964.74 |
| March 2030 | 2,653.77 | 2,041.36 |
| April 2030 | 2,601.74 | 2,001.34 |
| May 2030 | 2,525.96 | 1,943.05 |
| June 2030 | 2,639.63 | 2,030.48 |
| July 2030 | 2,587.87 | 1,990.67 |
| August 2030 | 2,667.91 | 2,052.24 |
| September 2030 | 2,761.28 | 2,124.06 |
| October 2030 | 2,833.08 | 2,179.29 |
| November 2030 | 2,903.90 | 2,233.77 |
| December 2030 | 2,976.50 | 2,289.62 |
Amrutanjan Healthcare Financials: Last 5 years
| Financials | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Sales (Rs. Cr) | 253 | 261 | 333 | 406 | 380 | 421 |
| Expenses (Rs. Cr) | 222 | 231 | 258 | 326 | 335 | 369 |
| Operating Profit (Rs. Cr) | 31 | 31 | 75 | 80 | 45 | 52 |
| OPM (%) | 12% | 12% | 22% | 20% | 12% | 12% |
| Other Income (Rs. Cr) | 7 | 8 | 11 | 15 | 15 | 16 |
| Interest (Rs. Cr) | 0 | 0 | 1 | 1 | 0 | 0 |
| Depreciation (Rs. Cr) | 3 | 4 | 4 | 4 | 5 | 6 |
| Profit Before Tax (Rs. Cr) | 35 | 34 | 82 | 91 | 54 | 62 |
| Tax % | 29% | 27% | 25% | 26% | 26% | 27% |
| Net Profit (Rs. Cr) | 25 | 25 | 61 | 67 | 40 | 45 |
| EPS (Rs.) | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.55 |
| Dividend Payout (%) | 26% | 24% | 20% | 20% | 34% | 23% |
Over the past five years, Amrutanjan Health Care Ltd has demonstrated significant growth and stability in its financial performance. From 2019 to 2024, the company’s sales steadily increased from Rs. 253 crore to Rs. 421 crore. Despite rising expenses, which climbed from Rs. 222 crore to Rs. 369 crore, Amrutanjan managed to consistently improve its operating profit, reaching Rs. 52 crore in 2024 from Rs. 31 crore in 2019.
Notably, the operating profit margin (OPM) showed strong improvement in 2021, hitting 22%, before stabilizing at 12% in subsequent years. The company’s strategic management of other income, minimal interest expenses, and controlled depreciation contributed to sustaining profitability. Amrutanjan’s net profit rose from Rs. 25 crore in 2019 to Rs. 45 crore in 2024, supporting a healthy earnings per share (EPS) growth trajectory, reflecting positively on shareholder returns despite varying dividend payout percentages over the period
FAQs
The share price target of Amrutanjan Healthcare for 2025 is ₹1,094.46.
The share price target of Amrutanjan Healthcare for 2030 is ₹2,976.50.
The share price target of Amrutanjan Healthcare in next 5 years will be around ₹2,976.50.
Also read:
- HINDALCO INDUSTRIES SHARE PRICE TARGET
- JK TYRE AND INDUSTRIES SHARE PRICE TARGET
- KOTAK MAHINDRA SHARE PRICE TARGET
Amrutanjan’s stock presents a mixed picture. The company has shown consistent sales growth over the past 10 years, 5 years, and 3 years, with compounded growth rates ranging from 11% to 13%. However, recent trailing twelve months (TTM) sales have declined by -6%. Similarly, Amrutanjan has achieved compounded profit growth over the long term, but the TTM profit growth stands at a significant -41%. The stock price has experienced positive compound annual growth rates over the past 10 years, 5 years, and 3 years, but it has declined by -6% in the last year.
While the company’s return on equity (ROE) has been consistently strong, the recent year’s ROE decreased to 14%. Given these factors, investors should thoroughly evaluate the recent decline in sales and profitability, as well as consider their investment objectives and risk tolerance before making any decisions regarding Amrutanjan’s stock.
What did we learn?
- 1 Amrutanjan Health Care Ltd Excels with Strong Revenue Growth but Faces Quarterly Profit Margin Challenges
- 2 How to purchase Amrutanjan Health Care Shares?
- 3 Amrutanjan Health Care Share Price Target: 2024 – 2030
- 4 Amrutanjan Healthcare Financials: Last 5 years
- 5 FAQs
- 6 Conclusion: Is Amrutanjan Healthcare a good share to buy in 2024?
